Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study

Safety Evaluation of Remdesivir for COVID-19 Patients with eGFR < 30 mL/min without Renal Replacement Therapy in a Japanese Single-Center Study

There are limited reports on the safety of remdesivir for patients with severe kidney disease. We investigated the safety of remdesivir administration for COVID-19 patients with estimated glomerular filtration rate (eGFR) <30 mL/min. This single-center retrospective study was conducted between Ma...

Full description

Bibliographic Details
Main Authors: Takumi Umemura, Yoshikazu Mutoh, Takahito Mizuno, Mao Hagihara, Hideo Kato, Tetsuya Yamada, Yoshiaki Ikeda, Hiroshige Mikamo, Toshihiko Ichihara
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Healthcare
Subjects:
remdesivir
renal impairment
SARS-CoV-2
eGFR
Online Access:https://www.mdpi.com/2227-9032/10/11/2299

Internet

https://www.mdpi.com/2227-9032/10/11/2299

Similar Items